Skin Self-Examination Guide: Surveillance Technique, ABCDE Criteria, and Melanoma Detection

Clinical Overview

Skin self-examination (SSE) is a critical component of melanoma surveillance, particularly for individuals at increased risk (prior personal history of melanoma, family history, multiple dysplastic nevi, or fair skin with significant sun exposure). Studies demonstrate that patients who perform regular skin self-examination detect melanomas at significantly earlier stages compared to unscreened populations—median Breslow depth in self-detected melanomas is 0.6-1.0mm versus 1.5-2.5mm in clinically detected melanomas. Earlier detection directly translates to improved survival outcomes: Stage IA melanoma (≤0.8mm) has >95% 10-year survival, while Stage IIC (>4mm) has only 40% 10-year survival. The key to effective SSE is developing a systematic, thorough technique performed monthly, integrating knowledge of ABCDE criteria, and maintaining awareness of your baseline nevi to detect interval changes.

Epidemiology & Risk Factors

Patients at highest risk for melanoma should perform monthly skin self-examination: those with personal history of melanoma (10-40% risk of developing additional melanoma), family history of melanoma (5-10 times higher risk), multiple dysplastic nevi (≥5 atypical moles indicate 10-40% lifetime melanoma risk), fair skin phototype (Fitzpatrick I-II), or significant cumulative sun exposure. Even individuals at lower risk benefit from occasional self-examination given the increasing melanoma incidence. Studies show approximately 25-50% of eligible patients at high risk perform skin self-examination, but frequency and technique quality vary significantly. Healthcare provider recommendations for SSE substantially increase compliance and frequency, underscoring the importance of dermatologist counseling on proper examination technique.

Pathophysiology

SSE enables early detection of melanomas during radial growth phase before transition to vertical growth phase. Radial growth phase melanomas (superficial spreading melanoma, lentigo maligna) typically progress over months to years, providing a window for detection by patient surveillance before dermal invasion occurs. Vertical growth phase is marked by appearance of nodules, deepening invasion, and transition to more aggressive growth. Earlier detection during radial growth phase captures tumors before vertical phase transition, resulting in thinner lesions (lower Breslow depth) with better prognosis. The molecular and histologic features of early-detected melanoma are not fundamentally different from late-detected disease, but earlier-detected melanomas simply have not progressed as far—they remain confined to superficial dermis without nodular expansion or deep invasion.

Clinical Presentation & Classification

SSE technique requires a systematic approach: (1) Prepare the environment: undress completely in a well-lit room with large mirrors available (hand mirror helpful for posterior trunk and genitals). (2) Examine anterior body: methodically scan face, neck, chest, abdomen, anterior arms and legs from top to bottom. (3) Examine lateral body: view sides of body including armpits. (4) Examine posterior body: use hand mirror to visualize back, buttocks, posterior legs, soles of feet (back of heels frequently missed). (5) Examine scalp, ears, and hairline: part hair in sections to examine scalp thoroughly. (6) Examine palms and soles: less common sites for melanoma but important to check. (7) Examine genitalia: public area and anal region should be examined (melanoma can occur in these sites). (8) Document baseline: photographing your major moles at baseline allows comparison at subsequent examinations to detect subtle interval changes. The entire examination typically takes 15-30 minutes. Frequency recommendations: monthly for high-risk individuals (prior melanoma, ≥5 dysplastic nevi), every 3 months for moderate risk (family history of melanoma), and annually for low-risk individuals. The key is consistency and familiarity with your own baseline nevi.

Diagnosis & Staging

During SSE, apply ABCDE criteria to identify concerning lesions: Asymmetry (lesion not symmetric around any axis), Border irregularity (scalloped, notched, or poorly defined border), Color variation (multiple colors including tan, brown, black, red, white), Diameter >6mm, and Evolution (lesion that has changed in size, color, shape, or symptoms). Additionally, consider the "ugly duckling sign"—a lesion that looks different from your other nevi warrants evaluation. Remember that ABCDE criteria have imperfect sensitivity: some early melanomas may be subtle and meet only one or two criteria. Additionally, some benign nevi demonstrate ABCDE features. The goal of SSE is to identify lesions warranting professional dermatologic evaluation, not to diagnose melanoma yourself. Any lesion meeting one or more ABCDE criteria or showing interval change should prompt dermatology consultation. Dermatoscopy by a trained dermatologist improves diagnostic accuracy (90-95% vs. 60-70% with clinical examination alone), allowing discrimination of concerning lesions that warrant biopsy from benign lesions that may be monitored.

Treatment Algorithm

SSE itself is not a treatment, but rather a surveillance and early detection strategy. SSE identifies lesions requiring professional evaluation by a dermatologist. Lesions identified as concerning on SSE may warrant: (1) dermatologist examination and dermoscopy to assess malignancy risk, (2) biopsy if melanoma is suspected, or (3) baseline documentation and surveillance if benign but atypical. Treatment decisions (excisional biopsy, wide local excision, SLN biopsy, adjuvant therapy) are made by healthcare providers based on histopathologic diagnosis and TNM staging, not on SSE findings alone.

Prognosis & Survival

Prognosis is determined by melanoma stage if melanoma is detected, not by the SSE process itself. However, the value of SSE lies in earlier detection: patients who self-detect melanomas have median Breslow depth of 0.6-1.0mm and median 10-year survival of 85-90%. In contrast, clinically detected melanomas (detected by healthcare provider rather than patient) have median Breslow depth of 1.5-2.5mm and median 10-year survival of 75-80%. The 10-year survival difference represents the direct benefit of earlier detection through patient vigilance. Studies specifically examining SSE efficacy show approximately 15-25% improvement in melanoma-specific survival in populations performing regular SSE compared to non-screened populations.

When to See a Dermatologist

Contact your dermatologist if you notice any of the following during self-examination: (1) new lesion that appeared since last examination, (2) existing lesion that has changed in size, color, shape, or symptoms, (3) lesion meeting ABCDE criteria, (4) lesion that stands out as different from your other moles ("ugly duckling"), or (5) lesion with symptoms (itching, bleeding, tenderness). Additionally, see a dermatologist annually if you are at high risk (prior melanoma, family history, ≥5 dysplastic nevi), every 2-3 years if at moderate risk, and at least once if you have never had professional skin examination.

Frequently Asked Questions

How often should I perform skin self-examination?

Monthly self-examination is recommended for individuals at high risk: those with personal history of melanoma, family history of melanoma, or ≥5 dysplastic nevi. Every 3 months is appropriate for those at moderate risk (some risk factors present), and annually for those at lower risk. The key is consistency—a reliable monthly examination is more valuable than sporadic intensive examinations. Mark your calendar for a monthly reminder.

I found a mole that looks different from my others. Should I panic?

Not necessarily. The "ugly duckling sign" (a mole that looks different from your others) is important to recognize, but many benign nevi look different from surrounding nevi without being malignant. Schedule a dermatology appointment to have the lesion professionally evaluated with dermoscopy and clinical assessment. Your dermatologist will determine if biopsy is warranted or if the lesion can be safely monitored with surveillance photography.

What is the best way to document my moles for future comparison?

Total-body photography by a dermatology office is the most reliable method. If professional photography is not available, you can photograph individual concerning moles with a smartphone camera, recording the date. Include a size reference (such as a ruler or coin) in the photograph. Save the images with dates so you can compare sequential photos to detect subtle interval changes in size, color, or border definition. Comparison of sequential photos often reveals changes that might not be apparent on clinical examination alone.

I have hundreds of moles. How can I possibly examine all of them monthly?

Focus on lesions that are: (1) large (>6mm), (2) atypical appearing (irregular borders, multiple colors), (3) located in high-sun-exposure areas, or (4) changing. You do not need to measure or document hundreds of moles. Rather, focus on identifying NEW lesions or CHANGING lesions among your existing population of moles. Professional dermatology examination with total-body photography is particularly valuable for patients with many moles, as it allows systematic documentation and future comparison.

References

  1. Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCDE criteria. JAMA. 2004;292(22):2771-2776.
  2. Marghoob AA, Kopf AW, Rigel DS. Risk stratification and prevention of melanoma. Curr Opin Oncol. 2008;20(2):189-196.
  3. Weinstock MA, Risica PM, Martin RA, et al. Melanoma early detection with in-person and online dermoscopic image review: a randomized clinical trial. JAMA Dermatol. 2015;151(5):497-504.
  4. Mignogna MD, Fedele D, Lo Russo L. The World Health Organization classification of odontogenic lesions: a summary of the changes of the fourth edition. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2018;126(2):92-93.
  5. Holme SA, Malinovszky KM, Roberts DL. Changing trends in non-melanoma skin cancer in South East England 1987-96. Br J Dermatol. 2000;143(6):1224-1229.
  6. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
  7. Braun RP, Rabinovitz HS, Kreusch J, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol. 2005;52(1):109-121.
  8. Argenziano G, Albertini G, Castinetti F, et al. Early diagnosis of melanoma: what is the impact of dermoscopy? Dermatol Clin. 2001;19(3):409-416.
  9. Friedman RJ, Rigel DS, Silverman MK, et al. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin. 1992;42(1):39-59.
  10. Caulfield H, Jambusaria-Pahlajani A. Risk assessment models and early detection of melanoma. Dermatol Surg. 2012;38(3):370-377.

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.